

FAIM2 RABBIT PAB

货号: S217421

产品全名: FAIM2 兔多抗

基因符号: LFG; LFG2; NGP35; NMP35; TMBIM2

UNIPROT ID: Q9BWQ8 (Gene Accession - BC000051)

背景: FAIM2 (Fas apoptotic inhibitory molecule 2), also known as LFG (Protein lifeguard), TMBIM2 (Transmembrane BAX inhibitor motif-containing protein 2) and NMP35 (neural membrane protein 35), is a 316 amino acid multipass membrane protein that uniquely protects cells from Fas-induced apoptosis. Though widely expressed, FAIM2 expression is highest in hippocampus. FAIM2 contains seven transmembrane domains and resembles Bax Inhibitor-1, another anti-apoptotic protein.

抗原: Fusion protein of human FAIM2

经过测试的应用: ELISA, WB, IHC

推荐稀释比: IHC: 50-200;WB: 500-2000;ELISA: 2000-5000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse, Rat


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Metabolism, Cancer


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human ovarian cancer tissue using 217421(FAIM2 Antibody) at a dilution of 1/30(Cytoplasm).




In comparison with the IHC on the left, the same paraffin-embedded Human ovarian cancer tissue is first treated with the fusion protein and then with 217421(Anti-FAIM2 Antibody) at dilution 1/30.



The image on the left is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using 217421(Anti-FAIM2 Antibody) at a dilution of 1/30.



In comparison with the IHC on the left, the same paraffin-embedded Human cervical cancer tissue is first treated with fusion protein and then with D222335(Anti-FAIM2 Antibody) at dilution 1/30.



Gel: 8%SDS-PAGE, Lysate: 40 µg;
Lane 1-2: A172 cells, Raji cells;
Primary antibody: 217421(FAIM2 Antibody) at dilution 1/500;
Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution;
Exposure time: 30 seconds



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
